TW202200779A - Medium and method for improving cordycepin and pentostatin production of cordyceps militaris - Google Patents
Medium and method for improving cordycepin and pentostatin production of cordyceps militaris Download PDFInfo
- Publication number
- TW202200779A TW202200779A TW109120844A TW109120844A TW202200779A TW 202200779 A TW202200779 A TW 202200779A TW 109120844 A TW109120844 A TW 109120844A TW 109120844 A TW109120844 A TW 109120844A TW 202200779 A TW202200779 A TW 202200779A
- Authority
- TW
- Taiwan
- Prior art keywords
- medium
- cordyceps militaris
- cordycepin
- pentostatin
- oat
- Prior art date
Links
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 70
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 title claims abstract description 57
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 title claims abstract description 56
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 title claims abstract description 55
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 title claims abstract description 46
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229960002340 pentostatin Drugs 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 11
- 239000012138 yeast extract Substances 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims abstract description 10
- 229930182830 galactose Natural products 0.000 claims abstract description 8
- 239000001888 Peptone Substances 0.000 claims abstract description 3
- 108010080698 Peptones Proteins 0.000 claims abstract description 3
- 235000019319 peptone Nutrition 0.000 claims abstract description 3
- 239000002609 medium Substances 0.000 claims description 106
- 235000007319 Avena orientalis Nutrition 0.000 claims description 60
- 244000075850 Avena orientalis Species 0.000 claims description 59
- 239000007788 liquid Substances 0.000 claims description 24
- 235000013339 cereals Nutrition 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 238000005286 illumination Methods 0.000 claims description 9
- 244000061456 Solanum tuberosum Species 0.000 claims description 8
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 6
- 108010068370 Glutens Proteins 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 241000209140 Triticum Species 0.000 claims description 6
- 235000021307 Triticum Nutrition 0.000 claims description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- 241000371652 Curvularia clavata Species 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 244000077995 Coix lacryma jobi Species 0.000 claims description 3
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 3
- 235000021329 brown rice Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- -1 malt extract Substances 0.000 claims description 2
- 241000209763 Avena sativa Species 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 abstract description 31
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 description 33
- 238000011081 inoculation Methods 0.000 description 16
- 238000003306 harvesting Methods 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- 229940045184 malt extract Drugs 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000009630 liquid culture Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- 241000190633 Cordyceps Species 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000219051 Fagopyrum Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- OQSXKFHAAVKRAJ-HBPOCXIASA-N (2s,3r,5s)-2-(6-amino-7h-purin-8-yl)-5-(hydroxymethyl)oxolan-3-ol Chemical compound N1C=2C(N)=NC=NC=2N=C1[C@@H]1O[C@H](CO)C[C@H]1O OQSXKFHAAVKRAJ-HBPOCXIASA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000186988 Streptomyces antibioticus Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000223095 Trypanosoma evansi Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940109551 nipent Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mushroom Cultivation (AREA)
Abstract
Description
本發明係涉及一種提升蛹蟲草的蟲草素及噴司他丁產量的培養基及方法。具體而言,涉及一種透過固態培養的方式提升蛹蟲草的蟲草素及噴司他丁產量的培養基及方法。The invention relates to a culture medium and a method for improving the yield of cordycepin and pentostatin of Cordyceps militaris. Specifically, it relates to a medium and a method for increasing the yield of cordycepin and pentostatin of Cordyceps militaris by means of solid-state culture.
蛹蟲草(Cordyceps militaris ) 又稱為北冬蟲夏草,是一種蟲生蟲草,屬於子囊菌綱,其菌絲體及子實體的 70%酒精萃取物具有抗發炎及其他藥理作用。目前已知蛹蟲草具有的生理活性物質包括腺苷(Adenosine)、蟲草素(Cordycepin)、蟲草酸(Cordycepic acid 或稱甘露醇(D-mannitol))、多醣(polysaccharide)及可生成噴司他丁(Pentostatin)。腺苷已知可作為心臟衰竭的保護心臟及治療的藥物並可抑制中樞神經系統的神經傳導物質的釋出。蟲草酸具有利尿及抗氧化作用並可舒緩咳嗽及氣喘症狀。多醣有抗發炎、抗癌及免疫調節功能。 Cordyceps militaris , also known as Cordyceps militaris, is a Cordyceps species belonging to the class of Ascomycetes. The 70% alcohol extract of its mycelium and fruiting bodies has anti-inflammatory and other pharmacological effects. Currently known physiologically active substances of Cordyceps militaris include Adenosine, Cordycepin, Cordycepic acid (or D-mannitol), polysaccharide and pentostatin. (Pentostatin). Adenosine is known to act as a cardioprotective and therapeutic drug for heart failure and to inhibit the release of neurotransmitters in the central nervous system. Cordyceps has diuretic and antioxidant properties and relieves cough and asthma symptoms. Polysaccharides have anti-inflammatory, anti-cancer and immunomodulatory functions.
蟲草素之化學式C10
H13
N5
O3
如式1所示,分子量為251.24,化學名依IUPAC命名為9-(3-deoxy-β-D-ribofuranosyl)adenine,或稱為3’-deoxyadenosine,其構造是腺嘌呤核苷的結構類似物。因此當合成RNA時,蟲草素取代腺嘌呤核苷被嵌入正在合成的RNA中,會使得合成的RNA不能被延長而結束合成RNA。研究指出蟲草素可能是以插入方式和與DNA的磷酸基團結合,而抑制DNA合成。式1The chemical formula of cordycepin C 10 H 13 N 5 O 3 is shown in
研究指出,蟲草素透過鈣離子-鈣蛋白酶-硫胱氨酸蛋白酶-多聚酶訊息傳遞路徑引起甲狀腺癌細胞凋亡。蟲草素可藉由與腺嘌呤受器結合,活化PKA傳遞路徑進而調控固醇類速控蛋白的表現以刺激小鼠萊氏細胞睪固酮之生成。並有研究推測蟲草素可以經由與腺嘌呤接受器作用後再去引發硫胱氨酸蛋白脢-9,-3以及-7的活化,最後使MA-10小鼠萊氏腫瘤細胞走向細胞凋亡的路徑。此外,有研究利用蛹蟲草水萃液用來處理人類肺癌A549細胞株,在動物初步實驗結果顯示,皮下給予蟲草素劑量為15 mg/kg之CMHW連續5天,能夠有效抑制腫瘤生長。將熱水萃取後之蛹蟲草發酵產物,分別對犬乳癌細胞株(DTK-SM2和DTK-SME-like)及人類乳癌細胞株(HCC1937)進行細胞培養,結果顯示當熱水萃取液含蟲草素 10μg/mL時,可誘導犬及人類乳癌細胞株產生凋亡小體,顯示蛹蟲草固態發酵產物之熱水萃取液,具有抗腫瘤之活性。Studies have shown that cordycepin induces apoptosis of thyroid cancer cells through the calcium ion-calpain-sulfatase-polymerase signaling pathway. Cordycepin can stimulate the production of testosterone in mouse Leyden cells by binding to adenine receptors, activating the PKA transmission pathway and regulating the expression of steroid rate-controlling proteins. And some studies speculate that cordycepin can trigger the activation of thiocysteine-9, -3 and -7 by interacting with adenine receptors, and finally make the MA-10 mouse Leyden tumor cells go to apoptosis. route of. In addition, some studies have used the water extract of Cordyceps militaris to treat human lung cancer A549 cell line. Preliminary animal experiments showed that subcutaneous administration of CMHW with a dose of 15 mg/kg of cordycepin for 5 consecutive days can effectively inhibit tumor growth. The fermented products of Cordyceps militaris after hot water extraction were cultured on canine breast cancer cell lines (DTK-SM2 and DTK-SME-like) and human breast cancer cell lines (HCC1937), respectively. The results showed that when the hot water extract contained cordycepin At 10μg/mL, canine and human breast cancer cell lines can be induced to produce apoptotic bodies, showing that the hot water extract of the solid-state fermentation product of Cordyceps militaris has antitumor activity.
噴司他丁(Penstostatin)化學式為C11
H16
N4
O4
,分子量=268.2691IUPAC命名為(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol,其化學結構見式二。式2Penstostatin (Penstostatin) chemical formula is C 11 H 16 N 4 O 4 , molecular weight = 268.2691 IUPAC named (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan- 2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol, its chemical structure is shown in formula II.
噴司他丁(Penstostatin(2'-deoxycoformycin))一開始是由被培養的土壤微生物(Streptomyces antibioticus)分離出,其結構與普林(purine)類似,可做為adenosine deaminase的抑制劑。1991年已獲FDA批准為治療毛細胞白血病的商業藥物(Nipent)。學術文獻目前已知對白血病相關疾病具治療功效,如慢性淋巴細胞性白血病、前淋巴細胞性白血病、皮膚T細胞淋巴瘤、成人T細胞淋巴瘤-白血病和低度非霍奇金淋巴瘤具抗腫瘤的活性。亦被用於治療毛細胞白血病及惰性淋巴增生性疾病。病例報告提出阿崙單抗(alemtuzumab)與噴司他丁組合能完全有效(Complete response)治療成人T細胞白血病(ATL)。噴司他丁對人體寄生蟲-鞭毛蟲(Trypanosoma spp.)的應用研究,研究中餵食蟲草素(2 mg/kg)與噴司他丁(0.2 mg/kg)的組合,能有效消滅被感染老鼠體內的Trypanosoma evansi。另有研究將單獨或蟲草素與噴司他丁的組合餵食被Trypanosom acruzi感染的老鼠,不能成功治癒,但是能減少心臟發炎的傷害。Penstostatin (2'-deoxycoformycin) was initially isolated from cultivated soil microorganisms (Streptomyces antibioticus), its structure is similar to purine, and it can be used as an inhibitor of adenosine deaminase. In 1991, it was approved by the FDA as a commercial drug (Nipent) for the treatment of hairy cell leukemia. Academic literature is currently known to have therapeutic efficacy against leukemia-related diseases such as chronic lymphocytic leukemia, prolymphocytic leukemia, cutaneous T-cell lymphoma, adult T-cell lymphoma-leukemia, and low-grade non-Hodgkin lymphoma tumor activity. It is also used to treat hairy cell leukemia and indolent lymphoproliferative diseases. Case reports suggest that alemtuzumab in combination with pentostatin is a complete response in the treatment of adult T-cell leukemia (ATL). Application study of pentostatin on human parasite-Trypanosoma spp. In the study, feeding the combination of cordycepin (2 mg/kg) and pentostatin (0.2 mg/kg) can effectively eliminate the infected Trypanosoma evansi in mice. Another study fed Trypanosom acruzi-infected mice alone or in combination with cordycepin and pentostatin, which was not successfully cured, but reduced damage from heart inflammation.
如上述,蛹蟲草可產生具有抗癌能力的蟲草素以及噴司他丁,並且其他種類的蟲草菌不會同時合成蟲草素跟噴司他丁。因此,本發明的一個目的在於提供一種能夠提升蛹蟲草的蟲草素及噴司他丁產量的培養基及提升蛹蟲草的蟲草素及噴司他丁產量方法。As mentioned above, Cordyceps militaris can produce cordycepin and pentostatin with anti-cancer ability, and other species of Cordyceps do not synthesize cordycepin and pentostatin at the same time. Therefore, an object of the present invention is to provide a medium capable of increasing the yield of cordycepin and pentostatin of Cordyceps militaris and a method for increasing the yield of cordycepin and pentostatin of Cordyceps militaris.
鑒於上述目的,本發明提供一種提升蛹蟲草的蟲草素及噴司他丁產量的方法,其包含:活化菌種,包含配製包含馬鈴薯葡萄糖基質的平板培養基,將各菌株的菌絲塊接種到平板培養基,於22-25°C培養活化;製備液體菌種,包含將接種有菌絲塊的平板培養基接入100mL的液體培養基,並在22-25°C、130-150rpm下培養1.5-2天以得到液體菌種;製備固體培養基,包含將穀物烘乾後,加入預定比例的RO水,並接入液體菌種進行培養;其中,培養過程包含維持22~25°C在暗室培養8~10天、以及維持16~19°C在照光環境下培養46~48天。In view of the above objects, the present invention provides a method for improving the yield of cordycepin and pentostatin of Cordyceps militaris, comprising: activating bacterial species, comprising preparing a plate medium comprising a potato glucose substrate, and inoculating the mycelium block of each strain on a plate Culture medium, cultivate and activate at 22-25 DEG C; prepare liquid bacterial species, comprise the liquid culture medium of inserting 100 mL of plate medium inoculated with mycelial block, and cultivate 1.5-2 days at 22-25 DEG C, 130-150rpm To obtain liquid strains; prepare solid culture medium, including drying the grains, adding a predetermined proportion of RO water, and inserting liquid strains for cultivation; wherein, the culturing process comprises maintaining 22-25 ° C and culturing in a dark room for 8-10 days, and maintained at 16-19°C for 46-48 days in a lighted environment.
較佳地,穀物包含黑米(Black rice) 、糙米(Brown rice) 、蕎麥(Buckwheat)、薏仁(Coix seed) 、燕麥(Oat)、裸麥(Pearl barly)及小麥(Wheat)。Preferably, the grains include Black rice, Brown rice, Buckwheat, Coix seed, Oat, Pearl barly and Wheat.
較佳地,穀物與RO水的比例為1:1.2~1:1.8。Preferably, the ratio of grain to RO water is 1:1.2~1:1.8.
較佳地,培養過程的光照環境為在白光100-1200 lux的照度以16-19°C培養46-48天。Preferably, the illumination environment in the cultivation process is to cultivate for 46-48 days at 16-19 ° C under the illumination of white light of 100-1200 lux.
較佳地,固體培養基進一步包含果糖、葡萄糖、半乳糖(galactose)、蛋白腖(peptone)、酵母萃取物、麥芽萃取物、腺苷單磷酸、甘胺酸、天門冬胺酸與麩醯胺中的至少一種。Preferably, the solid medium further comprises fructose, glucose, galactose, peptone, yeast extract, malt extract, adenosine monophosphate, glycine, aspartic acid and glutamine. at least one of.
依據本發明一實施例,本發明進一步提供一種提升蛹蟲草的蟲草素及噴司他丁產量的固態培養基,每一份包含:3~6mL前培養基,其含有蛹蟲草菌株;30g燕麥培養基,燕麥培養基與水的體積比為1.2~1.8;以及添加物。According to an embodiment of the present invention, the present invention further provides a solid medium for improving the yield of cordycepin and pentostatin of Cordyceps militaris, each portion comprising: 3-6 mL of a pre-medium containing strains of Cordyceps militaris; 30 g of oat medium, oat The volume ratio of medium to water is 1.2 to 1.8; and additives.
較佳地,前培養基為馬鈴薯葡萄糖培養基、麥芽萃取培養基或酵母麥芽萃取培養基。Preferably, the pre-medium is potato dextrose medium, malt extract medium or yeast malt extract medium.
較佳地,添加物為0.5~1.5wt%的果糖、半乳糖、葡萄糖、蛋白腖、麥芽萃取物或酵母萃取物中的至少一種。Preferably, the additive is 0.5-1.5 wt% of at least one of fructose, galactose, glucose, protein gluten, malt extract or yeast extract.
較佳地,添加物為10~100ppm的腺苷單磷酸、甘胺酸、天門冬胺酸與麩醯胺中的至少一種。Preferably, the additive is 10-100 ppm of at least one of adenosine monophosphate, glycine, aspartic acid and glutamine.
藉由上述技術特徵,本發明所提供的提升蛹蟲草產生的蟲草素及噴司他丁的培養基及方法至少具有以下優點:By the above-mentioned technical features, the culture medium and method for improving cordycepin and pentostatin produced by Cordyceps militaris provided by the present invention have at least the following advantages:
(1) 藉由本發明一實施例所提供之方法,可以提升蛹蟲草子的蟲草素與噴司他丁的產量。(1) The yield of cordycepin and pentostatin of Cordyceps militaris seeds can be improved by the method provided by an embodiment of the present invention.
(2) 透過本發明一實施例所提供的培養基,可以提升蛹蟲草中蟲草素與噴司他丁的濃度。(2) The concentration of cordycepin and pentostatin in Cordyceps militaris can be increased through the medium provided by an embodiment of the present invention.
(3) 透過本發明另一實施例所提供的培養基,可以提升蛹蟲草子實體的產量。(3) Through the medium provided by another embodiment of the present invention, the yield of the fruiting bodies of Cordyceps militaris can be improved.
在以下描述中,出於解釋的目的,闡述了許多具體細節以便提供對本發明的各種例示性實施例或實現的透徹理解。然而,顯而易見的是,可以在沒有這些具體細節的情況下或者利用一個或多個等效配置來實踐各種例示性實施例。此外,各種例示性實施例可以是不同的,但不必是排他的。例如,在不脫離本發明構思的情況下,可以在另一例示性實施例中使用或實現例示性實施例的特定形狀、配置和特性。In the following description, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of various exemplary embodiments or implementations of the present invention. It will be apparent, however, that various illustrative embodiments may be practiced without these specific details or with one or more equivalent arrangements. Furthermore, the various exemplary embodiments may vary, but are not necessarily exclusive. For example, the specific shapes, configurations, and characteristics of an exemplary embodiment may be used or implemented in another exemplary embodiment without departing from the inventive concept.
除非另外定義,否則本文使用的所有術語(包含技術和科學術語)具有與本發明所屬領域具有通常知識者通常理解的含義相同的含義。例如在常用詞典中定義的術語,應被解釋為具有與相關領域中它們的含義一致的含義,並且不應以理想化或過於正式的意義來解釋,除非在此明確定義。Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms defined in common dictionaries, for example, should be interpreted as having meanings consistent with their meanings in the relevant art, and should not be interpreted in an idealized or overly formal sense unless explicitly defined herein.
本文中所述的數值範圍可以包含在該範圍內的具有相同數值精確度的所有子範圍。例如,範圍「1.0至10.0」可以包含最小值1.0及最大值10.0之間的所有子範圍,也就是具有等同於或大於1.0的最小值及等同於或小於10.0的最大值,例如,2.4至7.6。任何本文所述的最大數值限制可以包含所有較低的數值限制,且本說明書中所述的所有最小數值限制可以包含所有較高的數值限制。相應的,申請人保留修改本說明書(包含申請專利範圍)的權利,以明確列舉包含在本文明確敘述的範圍內的任何子範圍。所有的這些範圍係為在本說明書中固有的描述。Numerical ranges recited herein can include all subranges within that range with the same numerical precision. For example, the range "1.0 to 10.0" may include all subranges between a minimum value of 1.0 and a maximum value of 10.0, that is, with a minimum value equal to or greater than 1.0 and a maximum value equal to or less than 10.0, eg, 2.4 to 7.6 . Any maximum numerical limitation stated herein can include all lower numerical limitations, and all minimum numerical limitations stated in this specification can include all higher numerical limitations. Accordingly, the applicant reserves the right to amend this specification (including the claimed scope) to expressly recite any sub-ranges subsumed within the ranges expressly recited herein. All of these ranges are inherent in this specification.
本發明的研究中包含篩選最適合提升蛹蟲草的蟲草素及噴司他丁產量的前培養基、穀物培養基、培養條件以及最適合之培養基添加物。The research of the present invention includes screening the most suitable pre-medium, grain medium, culture conditions and the most suitable medium supplement for improving the production of cordycepin and pentostatin of Cordyceps militaris.
在本發明的各實施例中,菌種活化、液體菌種製備以及培養後子實體粉末的製備、腺苷/蟲草素/噴司他丁的測量方式如下:In each embodiment of the present invention, the methods for the activation of strains, the preparation of liquid strains, the preparation of fruit body powder after cultivation, and the measurement of adenosine/cordycepin/pentastatin are as follows:
菌種活化Strain activation
試驗菌株保存於4°C冰箱。進行試驗時,配置馬鈴薯葡萄糖 (Potato Dextrose Agar (PDA))平板培養基,將各菌株的菌絲塊接種到平板培養基,於22-25°C培養活化,經再一次活化後的菌株,即可進行後續試驗。試驗用菌株每2個月繼代培養一次,以避免菌種老化而易受污染。The test strains were stored in a refrigerator at 4°C. When carrying out the test, configure potato dextrose (Potato Dextrose Agar (PDA)) plate medium, the mycelium block of each bacterial strain is inoculated into plate medium, cultivate and activate at 22-25 DEG C, through the bacterial strain after activation again, can carry out follow-up test. The test strains were subcultured every 2 months to avoid the aging and contamination of the strains.
液體菌種製備Liquid strain preparation
試驗菌株配置液體培養基,將100 ml液體培養基置入300 ml的三角瓶中,於121°C、1.5 kg/cm2 滅菌20分鐘,冷卻後再將於平板培養基生長14天的菌絲塊(比例為2 cm2 /瓶)接入上述的液體培養基,在22-25°C、130-150 rpm下培養1.5-2天,即為液體菌種。Test bacterial strain configuration liquid culture medium, 100 ml liquid culture medium is inserted in the triangular flask of 300 ml, at 121 DEG C, 1.5 kg/cm 20 minutes of sterilization, after cooling, the mycelium block (ratio be 2 cm 2 /bottle) into the above-mentioned liquid culture medium, cultivate at 22-25 ° C, 130-150 rpm for 1.5-2 days, namely liquid bacterial species.
子實體粉末製備Fruit body powder preparation
將採樣的子實體置於50°C烘箱內烘乾至恆重,以磨粉機粉碎後過篩(40 mesh)即得子實體粉末。The sampled fruit bodies were placed in a 50°C oven and dried to constant weight, pulverized with a pulverizer and then sieved (40 mesh) to obtain fruit body powder.
子實體中蟲草素與噴司他丁的測定Determination of Cordycepin and Pentostatin in Fruiting Body
萃取方法如下,子實體粉末加入50倍體積ddH2 O,超音波萃取20分鐘,再經14,000 rpm 離心20分鐘,收集上清液,經0.45μm微孔濾膜過濾後,以高效能液相層析儀 (high performance liquid chromatograph, HPLC) 分析蟲草素與噴司他丁的含量。The extraction method is as follows: add 50 times the volume of ddH 2 O to the fruit body powder, extract by ultrasonic for 20 minutes, and then centrifuge at 14,000 rpm for 20 minutes, collect the supernatant, filter it through a 0.45 μm microporous membrane, and filter it with a high-efficiency liquid phase layer. The content of cordycepin and pentostatin was analyzed by high performance liquid chromatograph (HPLC).
蟲草素及噴司他丁之HPLC分析條件如下: 分離管柱:Hypersil GOLD column (5 μm; Thermo Fisher Scientific Inc., Waltham, MA)。 注射量:10 μL。 偵測波長:UV 260 nm (ultraviolet/visible light detector (UV-2075 Plus; JASCO, Co. Ltd., Tokyo, Japan))。 移動相:85% KH2 PO4 + 15% 甲醇。 流速:0.5 mL/min。The HPLC analysis conditions of cordycepin and pentostatin are as follows: Separation column: Hypersil GOLD column (5 μm; Thermo Fisher Scientific Inc., Waltham, MA). Injection volume: 10 μL. Detection wavelength: UV 260 nm (ultraviolet/visible light detector (UV-2075 Plus; JASCO, Co. Ltd., Tokyo, Japan)). Mobile phase: 85% KH 2 PO 4 + 15% methanol. Flow rate: 0.5 mL/min.
接著進行最適穀物培養基的篩選。Screening of the most suitable grain medium is then carried out.
穀物培養之製備及篩選Preparation and screening of grain cultures
參考第1圖及第2圖,第1圖係為依據本發明實施例的蛹蟲草在不同穀物及不同培養模式的生長狀況。第2圖係為依據本發明實施例的蛹蟲草在不同穀物及不同培養模式的收穫結果比較。Referring to FIG. 1 and FIG. 2, FIG. 1 shows the growth status of Cordyceps militaris in different grains and different cultivation modes according to an embodiment of the present invention. FIG. 2 is a comparison of harvesting results of Cordyceps militaris in different grains and different cultivation modes according to an embodiment of the present invention.
將3 mL 蛹蟲草液體菌種分別接種於30g不同穀物(黑米(Black rice)、糙米(Brown rice)、蕎麥(Buckwheat)、薏仁(Coix seed)、燕麥(Oat)、裸麥(Pearl barly)與小麥(Wheat))等七種穀物培養基並於兩種溫度控制模式進行培養,模式一為23 °C(暗室,9天)-18°C(照光,47天) ,模式二為23 °C(暗室,9天)-18 °C(照光,5天)-23 °C(照光,42天)。第1圖是以模式一(23 °C(暗室,9天)-18 °C(照光,47天)) 進行培養之蛹蟲草生長狀態,第1圖顯示蛹蟲草之原基體於照光後第5天已出現,第12天則生長明顯,第33天蛹蟲草生長於燕麥(Oat)培養基之子實體高度已達到培養瓶瓶口,到第47天培養結束時,除蕎麥、大薏仁及黑米外,蛹蟲草 於其餘穀物培養基生長之子實體高度已充滿培養瓶,但是生長的子實體密度及粗細,影響最後的總產量。
第2圖中可以看到子實體的乾重較高的培養基分別為燕麥培養基(模式一,第56天,5.88±0.0.14 g 乾重子實體/瓶;模式二,第56天,5.74±0.13g 乾重子實體/瓶)及裸麥培養基(模式一,第56天,5.68±0.19g 乾重子實體/瓶),子實體蟲草素含量較高則是薏仁培養基(模式二,第56天,8.06±0.08 mg/ g 乾重子實體),但其子實體產量低( 第56天,4.98±0.38 g 乾重子實體/瓶)且噴司他丁的含量第42天最高只有0.66±0.06 mg/ g 乾重子實體;其次則是小麥培養基(模式二,第56天,5.43±0.34 mg/ g 乾重子實體),但其子實體乾重亦低 (第56天最高為4.43±0.37g 乾重子實體/瓶)。而子實體噴司他丁的含量較高則有燕麥培養基(模式一,第42天,1.1.18±0.0.32 mg/ g 乾重子實體),但其蟲草素含量第56天為1.972.06±0.410.44 mg/ g 乾重子實體;蕎麥培養基則於模式一時,第42天噴司他丁的含量為1.28±0.12 mg/ g 乾重子實體,且其蟲草素含量第56天為3.99±0.89 mg/ g 乾重子實體,但其子實體乾重第56 天只有4.22±0.17g 乾重子實體/瓶。此外,在此實施例的使用蕎麥培養基、燕麥培養基、裸麥培養基以及小麥培養基的情況下,發酵穀物(fermented grains,即長有菌絲之培養基)中的蟲草素含量高於子實體中的蟲草素含量,且蟲草素含量隨時間推移呈上升趨勢。In Figure 2, it can be seen that the medium with higher dry weight of fruiting bodies is oat medium (mode one,
接著是液體菌種之最適培養基試驗。Next is the optimum medium test for liquid strains.
參考第3圖及第4圖,第3圖係為依據本發明實施例的不同液體菌種培養基的生長狀況。第4圖係為依據本發明實施例的不同液體菌種培養基的收穫結果比較。Referring to Fig. 3 and Fig. 4, Fig. 3 shows the growth conditions of different liquid culture mediums according to an embodiment of the present invention. FIG. 4 is a comparison of harvesting results of different liquid culture media according to an embodiment of the present invention.
分別將蛹蟲草菌絲塊植入馬鈴薯葡萄糖 (potato dextrose Broth,PDB) 培養基、麥芽萃取(Malt Extract Broth,MEB) 培養基、酵母麥芽萃取(Yeast extract Malt Broth,YMB) 培養基,培養1.5天,即為試驗用的液體菌種,再取3 mL接種於30g燕麥培養基,以模式一(23 °C(9天,暗室)-18 °C(47天,照光)) 進行培養之生長狀態,第3圖為蛹蟲草顯示蛹蟲草之原基體於照光後第12天則生長明顯,第40天蛹蟲草之子實體高度皆已達到培養瓶瓶口,到第47天培養結束時,可觀察到生長的子實體密度及粗細有明顯差異,而影響最後的總產量。測定接種後第 42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量如第4圖所示。實驗結果顯示當前培養基使用酵母麥芽萃取培養基時,可得到較高的子實體的乾重(第56天,6.26±0.09 g 乾重子實體/瓶),但是前培養基使用對照組馬鈴薯葡萄糖培養基時,子實體的蟲草素與噴司他丁含量較高(第56天為1.97±0.41 mg/ g 乾重子實體;第42天,1.18±0.32 mg/ g乾重子實體) 。此外,在此實施例中,發酵穀物中的蟲草素含量也呈現增加趨勢,在酵母麥芽萃取培養基中的蟲草素含量也高於子實體。Cordyceps militaris mycelium pieces were implanted into potato dextrose (PDB) medium, malt extract (MEB) medium, and yeast extract Malt Broth (YMB) medium, respectively, and cultured for 1.5 days. That is, the liquid strain used for the test, and then take 3 mL and inoculate it in 30g oat medium, and carry out the growth state of cultivation in mode one (23 °C (9 days, dark room)-18 °C (47 days, light)). Figure 3 shows that the original matrix of Cordyceps militaris shows obvious growth on the 12th day after the illumination, and the height of the fruiting body of Cordyceps militaris has reached the bottle mouth of the culture bottle on the 40th day. The density and thickness of the fruiting bodies were significantly different, which affected the final total yield. The dry weight, cordycepin and pentostatin content of the fruiting bodies on the 42nd, 50th and 56th days after inoculation were determined as shown in Figure 4. The experimental results showed that when the current medium used yeast malt extraction medium, higher dry weight of fruit bodies (56th day, 6.26±0.09 g dry weight fruit bodies/bottle) was obtained, but when the former medium used the control potato glucose medium, The content of cordycepin and pentostatin in the fruiting bodies was higher (1.97±0.41 mg/g dry weight fruiting body on
再來是決定液體菌種之最適接種量。The next step is to determine the optimal inoculum size for liquid strains.
參考第5圖及第6圖,第5圖係為依據本發明實施例的不同液體菌種接種量生長狀況。第6圖係為依據本發明實施例的不同液體菌種接種量的收穫結果比較。Referring to FIG. 5 and FIG. 6, FIG. 5 shows the growth status of different liquid bacterial inoculum amounts according to an embodiment of the present invention. FIG. 6 is a comparison of harvesting results of different liquid bacterial inoculation amounts according to an embodiment of the present invention.
蛹蟲草液體菌種接入30g的燕麥培養基,分別為 3 ml/瓶(接種量10 %,v/w)、4.5 ml/瓶(接種量15 %,v/w) 與 6 ml/瓶 (接種量20 %,v/w),之後以模式一(23 °C(暗室,9天)-18 °C(照光,47天)) 進行培養之蛹蟲草生長狀態,如第5圖所示,由圖顯示蛹蟲草之原基體於照光後第12天則生長明顯,第40天蛹蟲草之子實體高度皆已達到培養瓶瓶口,到第47天培養結束時,可觀察到生長的子實體密度及粗細有明顯差異,以接種6 ml/瓶 (接種量20 %,v/w) 的子實體密度較高且子實體較細。測定接種後第 42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量,實驗結果見第6圖。實驗結果顯示隨接種量增加,子實體的產量亦增加,接種量為 6 ml/瓶 (接種量20 %,v/w)時,可得到較高的子實體的乾重(第56天,6.52±0.16 g 乾重子實體/瓶)。但是對照組(接種量 3 mL)生成的子實體蟲草素與噴司他丁含量較高(第56天為1.97±0.41 mg/ g 乾重子實體;第42天,1.18±0.32 mg/ g乾重子實體)。Cordyceps militaris liquid strain accesses 30g oat medium, respectively 3 ml/bottle (
接下來是關於燕麥培養基的最適水分比例。Next is the optimum water ratio for oat medium.
參考第7圖及第8圖,第7圖係為依據本發明實施例的燕麥培養基在不同水分比例的生長狀況。第8圖係為依據本發明實施例的燕麥培養基在不同水分比例的收穫結果比較。Referring to Figures 7 and 8, Figure 7 shows the growth conditions of the oat medium in different water ratios according to an embodiment of the present invention. FIG. 8 is a comparison of the harvesting results of the oat medium in different water ratios according to the embodiment of the present invention.
分別將 3 mL 蛹蟲草液體菌種接入不同燕麥與水之比例的燕麥培養基,燕麥培養基之燕麥與水之比例 (w/v) 分別為1(30 g):1.2(36 ml)、1(30 g):1.5(45 ml)及1(30 g):1.8(54 ml),進行模式一培養,第7圖顯示蛹蟲草進行培養之生長狀態,可知蛹蟲草之原基體於照光後第12天則生長明顯,到第40天燕麥與水比例為 1:1.5及1:1.8的燕麥培養基生長的子實體高度皆已達到培養瓶瓶口,到第47天培養結束時,可觀察到1:1.8的燕麥培養基生長之子實體密度較高且子實體較細。而1:1.2的燕麥培養基生長之子實體密度則稀疏。 測定接種後第42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量,如8圖所示,實驗結果顯示隨水分比例增加,子實體的產量亦增加,當燕麥對水分比例為1:1.8時,可得到子實體產量最高(第56天,6.68±0.85 g 乾重子實體/瓶),但是當燕麥對水分比例為1:1.2時,則是蛹蟲草子實體的蟲草素與噴司他丁含量較高 (第56天為2.37±1.31 mg/ g 乾重子實體;第42天,1.47±0.47 mg/ g 乾重子實體)。此外,在此實施例中,第8圖中可看出在水份比例為1:1.2時,子實體中的蟲草素含量隨時間推移提高,明顯高於其他兩組,且發酵穀物中所含的蟲草素含量在各時間點也略高於其他兩組。3 mL of Cordyceps militaris liquid strains were added to oat medium with different ratios of oats and water, respectively. 30 g): 1.5 (45 ml) and 1 (30 g): 1.8 (54 ml), carry out
以下將透過本發明實施例討論對穀物培養基中添加不同添加物對培養之蛹蟲草的影響。The following will discuss the effects of adding different additives to the grain medium on the cultured Cordyceps militaris through the examples of the present invention.
首先是在燕麥培養基中添加不同碳源的試驗。The first is the experiment of adding different carbon sources to the oat medium.
參考第9圖及第10圖,第9圖係為依據本發明實施例的燕麥培養基添加不同碳源的生長狀況。第10圖係為依據本發明實施例的燕麥培養基添加不同碳源的收穫結果比較。Referring to Figures 9 and 10, Figure 9 shows the growth conditions of the oat medium supplemented with different carbon sources according to an embodiment of the present invention. Fig. 10 is a comparison of the harvesting results of adding different carbon sources to the oat medium according to the embodiment of the present invention.
分別將 3 mL 蛹蟲草液體菌種接入分別含1% 果糖、半乳糖、葡萄糖的30g的燕麥培養基,進行模式一培養,第9圖顯示蛹蟲草進行培養之生長狀態,可知蛹蟲草之原基體於照光後第12天則生長明顯,到第47天培養結束時,可觀察到加入葡萄糖的燕麥培養基生長之蛹蟲草子實體密度較疏,而加入半乳糖的燕麥培養基生長的子實體密度較高。 第10圖顯示蛹蟲草 第 42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量變化。實驗結果顯示蛹蟲草培養於添加碳源的燕麥培養基之接種後第42天的子實體產量相對於未添加碳源的對照組較低,但是第56天子實體產量都較高,其中以半乳糖對增加子實體產量(6.10±0.30 g 乾重子實體/瓶)最為顯著。但是未添加碳源的對照組之蛹蟲草子實體的蟲草素含量較高(第56天為1.97±0.41 mg/ g 乾重子實體),添加半乳糖的燕麥培養基生成的子實體含噴司他丁含量較高(第42天,1.27±0.34mg/ g乾重子實體) )。3 mL of Cordyceps militaris liquid strains were respectively inserted into 30 g of oat medium containing 1% fructose, galactose, and glucose, respectively, to carry out mode one cultivation. Figure 9 shows the growth state of Cordyceps militaris cultured, and it can be seen that the original matrix of Cordyceps militaris The growth is obvious on the 12th day after the illumination, and when the culture finishes on the 47th day, it can be observed that the density of the Cordyceps militaris fruiting body of the growth of the oat medium that adds glucose is sparse, and the density of the fruiting body of the growth of the oat medium that adds galactose is higher. . Figure 10 shows the changes in dry weight, cordycepin and pentostatin content of fruiting bodies of Cordyceps militaris on
接著是在燕麥培養基中添加不同氮源的試驗。This was followed by experiments with the addition of different nitrogen sources to the oat medium.
參考第11圖及第12圖,第11圖係為依據本發明實施例的燕麥培養基添加不同氮源的生長狀況。第12圖係為依據本發明實施例的燕麥培養基添加不同氮源的收穫結果比較。Referring to Fig. 11 and Fig. 12, Fig. 11 shows the growth conditions of the oat medium supplemented with different nitrogen sources according to an embodiment of the present invention. FIG. 12 is a comparison of the harvesting results of adding different nitrogen sources to the oat medium according to the embodiment of the present invention.
分別將 3 mL 蛹蟲草液體菌種接入含1% 麥芽萃取物、蛋白腖、酵母萃取物的30g的燕麥培養基,進行模式一培養,第11圖顯示蛹蟲草進行培養之生長狀態,可知蛹蟲草之原基體於照光後第12天則生長明顯,到第33天時以對照組及加入麥芽萃取物的燕麥培養基之子實體生長較佳,加入蛋白腖及酵母菌萃取物則是培養後期才生長較快。3 mL of the liquid strain of Cordyceps militaris was added to 30 g of oat medium containing 1% malt extract, protein gluten, and yeast extract, respectively, for
第12圖顯示蛹蟲草接種後第 42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量變化。實驗結果顯示蛹蟲草培養於添加蛋白腖的燕麥培養基之第56天子實體產量(6.10±0.30g 乾重子實體/瓶)相對於未添加的對照組(5.87±0.14g 乾重子實體/瓶)較高,但是添加酵母菌萃取物的燕麥培養基之第56天子實體產量(5.26±0.22g 乾重子實體/瓶)相對於未添加的對照組則減少,即添加 1%酵母菌萃取物不能提高蛹蟲草子實體產量。但是未添加的對照組之蛹蟲草子實體的蟲草素含量較高(第56天,1.97±0.41 mg/ g 乾重子實體),而添加蛋白腖的燕麥培養基之子實體噴司他丁含量最高(第42天,1.46±0.20 mg/ g 乾重子實體 )。此外,在加入氮源的情況下,發酵穀物中的蟲草素含量在各時間點都高於子實體中的蟲草素含量。Figure 12 shows the changes in the dry weight of the fruiting bodies, the content of cordycepin and pentostatin on the 42nd, 50th and 56th days after inoculation of Cordyceps militaris. The experimental results showed that the fruiting body yield (6.10±0.30g dry weight fruiting body/bottle) of Cordyceps militaris cultured in the oat medium supplemented with protein gluten on the 56th day was higher than that of the unadded control group (5.87±0.14g dry weight fruiting body/bottle), However, the yield of fruiting bodies on the 56th day (5.26±0.22g dry weight fruiting bodies/bottle) of the oat medium supplemented with yeast extract decreased compared with the control group without addition, that is, adding 1% yeast extract could not improve the fruiting bodies of Cordyceps militaris Yield. However, the Cordyceps militaris fruiting body of the unsupplemented control group had a higher content of cordycepin (
最後是在燕麥培養基中添加其他添加物的試驗。The last is the experiment of adding other supplements to the oat medium.
參考第13圖至第15圖,第13圖係為依據本發明實施例的燕麥培養基添加不同添加物的生長狀況。第14圖係為依據本發明實施例的燕麥培養基添加不同添加物的生長狀況。第15圖係為依據本發明實施例的燕麥培養基添加不同添加物的收穫結果比較。Referring to Fig. 13 to Fig. 15, Fig. 13 shows the growth status of the oat medium with different additives according to the embodiment of the present invention. Fig. 14 shows the growth conditions of the oat medium with different additives according to the embodiment of the present invention. Fig. 15 is a comparison of the harvest results of the oat medium with different additives according to the embodiment of the present invention.
每瓶30 g的燕麥放入450 mL玻璃瓶,加入45 ml 含不同濃度(10 ppm、100ppm) 的腺苷單磷酸 (Adenosine monophosphate, AMP)、甘胺酸(Glycine)、天門冬胺酸(Aspartic acid)與麩醯胺(Glutamine),滅菌完成後,接入3 mL 蛹蟲草液體菌種進行模式一培養,第13圖顯示濃度為10 ppm時蛹蟲草進行培養之生長狀態,第14圖顯示濃度為100 ppm時蛹蟲草之生長狀態,由上述二圖可知添加上述化學物不會不利蛹蟲草之原基體生成,且子實體生長亦是良好。Each bottle of 30 g oats was put into a 450 mL glass bottle, and 45 mL of different concentrations (10 ppm, 100 ppm) of adenosine monophosphate (AMP), glycine (Glycine), and aspartic acid (Aspartic acid) were added. acid) and glutamine (Glutamine), after the sterilization is completed, add 3 mL of Cordyceps militaris liquid strain for
第15圖顯示蛹蟲草接種後第 42、50 及 56 天的子實體的乾重、蟲草素與噴司他丁的含量變化。實驗結果顯示蛹蟲草培養於添加試驗用的10-100ppm前驅物的燕麥培養基之第56天的子實體產量 (5.97-6.32 g 乾重子實體/瓶) 相對於未添加的對照組(5.5.87±0.14g 乾重子實體/瓶) 皆較高,且第42天子實體產量並未顯著性降低,其中100 ppm腺苷單磷酸(6.32±0.40g 乾重子實體/瓶)與(6.32±0.13g 乾重子實體/瓶) 對增加子實體產量最為顯著。添加100 ppm天門冬胺酸之蛹蟲草子實體的蟲草素含量(第56天,2.42±0.32 mg/ g 乾重子實體 )較未添加的對照組高,但是添加前驅物的的燕麥培養基生成的蛹蟲草子實體的噴司他丁含量(第42天,0.42-1.01 mg/ g 乾重子實體)皆低於未添加的對照組。Figure 15 shows the changes in the dry weight of the fruiting bodies, the content of cordycepin and pentostatin on the 42nd, 50th and 56th days after inoculation of Cordyceps militaris. The experimental results show that the fruit body yield of Cordyceps militaris cultured in the oat medium supplemented with 10-100ppm of the precursor used in the test on the 56th day (5.97-6.32 g dry weight fruiting body/bottle) relative to the unadded control group (5.5.87± 0.14g dry weight fruiting bodies/bottle) were higher, and the yield of fruiting bodies on the 42nd day did not decrease significantly, among which 100 ppm adenosine monophosphate (6.32±0.40g dry weight fruiting bodies/bottle) and (6.32±0.13g dry weight fruiting bodies) and (6.32±0.13g dry weight fruiting bodies) body/bottle) was the most significant for increasing fruit body yield. Cordycepin content of the fruiting bodies of Cordyceps militaris supplemented with 100 ppm aspartic acid (
從上述結果可知,在蛹蟲草的前培養基使用馬鈴薯葡萄糖培養基、接種量 3 mL/瓶於燕麥培養基,燕麥培養基的燕麥對水分比例為1:1.2,並添加酵母萃取物能生成相對高含量的蟲草素與噴司他丁的子實體。而前培養基使用酵母麥芽萃取培養基、接種量 6 ml/瓶、燕麥對水分比例為1:1.8,並添加半乳糖與蛋白腖於燕麥培養基能獲得高產量的子實體。在使用依據本發明實施例的培養基時,除了子實體之外,在發酵穀物中也具有高含量的蟲草素。It can be seen from the above results that potato glucose medium was used in the pre-medium of Cordyceps militaris, and the inoculum amount was 3 mL/bottle in the oat medium. The oat-to-moisture ratio of the oat medium was 1:1.2, and the addition of yeast extract could generate relatively high content of Cordyceps The fruiting bodies of vegan and pentostatin. The pre-medium used yeast malt extract medium, the inoculum volume was 6 ml/bottle, the ratio of oat to water was 1:1.8, and galactose and protein gluten were added to the oat medium to obtain high-yield fruit bodies. When the medium according to the embodiment of the present invention is used, in addition to the fruit body, the fermented grain also has a high content of cordycepin.
藉此,在透過培養蛹蟲草生產蟲草素與噴司他丁時,可以依據硬體設備、環境、人力等限制要求,選擇能夠提供高含量的生產方式,或是選擇能夠提供高產量的生產方式,進而達到提升效率、節省生產成本的效果。In this way, when producing cordycepin and pentostatin by cultivating Cordyceps militaris, a production method that can provide high content or a production method that can provide high yield can be selected according to the constraints of hardware equipment, environment, manpower, etc. , and then achieve the effect of improving efficiency and saving production costs.
儘管本文已經描述了某些例示性實施例和實現,但是根據該描述,其他實施例和修改將是顯而易見的,因此,本發明構思不限於這些實施例,而是限於所附申請專利範圍的更寬範圍以及對於本領域具有通常知識者顯而易見的各種明顯的修改和等效配置。While certain illustrative embodiments and implementations have been described herein, other embodiments and modifications will be apparent from this description and, therefore, the inventive concepts are not limited to these embodiments, but rather to broader aspects of the scope of the appended claims. Wide range and various obvious modifications and equivalent arrangements that will be apparent to those of ordinary skill in the art.
無none
以下包含附圖說明以提供對本發明的進一步理解,並且其被併入並構成本說明書的一部分,附圖示出了本發明的例示性實施例,並且與說明書一起用於解釋本發明構思。 第1圖係為依據本發明實施例的蛹蟲草在不同穀物及不同培養模式的生長狀況。 第2圖係為依據本發明實施例的蛹蟲草在不同穀物及不同培養模式的收穫結果比較。 第3圖係為依據本發明實施例的不同液體菌種培養基的生長狀況。 第4圖係為依據本發明實施例的不同液體菌種培養基的收穫結果比較。 第5圖係為依據本發明實施例的不同液體菌種接種量生長狀況。 第6圖係為依據本發明實施例的不同液體菌種接種量的收穫結果比較。 第7圖係為依據本發明實施例的燕麥培養基在不同水分比例的生長狀況。 第8圖係為依據本發明實施例的燕麥培養基在不同水分比例的收穫結果比較。 第9圖係為依據本發明實施例的燕麥培養基添加不同碳源的生長狀況。 第10圖係為依據本發明實施例的燕麥培養基添加不同碳源的收穫結果比較。 第11圖係為依據本發明實施例的燕麥培養基添加不同氮源的生長狀況。 第12圖係為依據本發明實施例的燕麥培養基添加不同氮源的收穫結果比較。 第13圖係為依據本發明實施例的燕麥培養基添加不同添加物的生長狀況。 第14圖係為依據本發明實施例的燕麥培養基添加不同添加物的生長狀況。 第15圖係為依據本發明實施例的燕麥培養基添加不同添加物的收穫結果比較。The following description of the accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate exemplary embodiments of the invention and together with the description serve to explain the inventive concept. FIG. 1 shows the growth status of Cordyceps militaris in different grains and different culture modes according to an embodiment of the present invention. FIG. 2 is a comparison of harvesting results of Cordyceps militaris in different grains and different cultivation modes according to an embodiment of the present invention. FIG. 3 shows the growth conditions of different liquid culture mediums according to an embodiment of the present invention. FIG. 4 is a comparison of harvesting results of different liquid culture media according to an embodiment of the present invention. FIG. 5 shows the growth conditions of different liquid bacterial inoculum amounts according to an embodiment of the present invention. FIG. 6 is a comparison of harvesting results of different liquid bacterial inoculation amounts according to an embodiment of the present invention. Fig. 7 shows the growth conditions of the oat medium at different water ratios according to an embodiment of the present invention. FIG. 8 is a comparison of the harvesting results of the oat medium in different water ratios according to the embodiment of the present invention. Fig. 9 shows the growth conditions of oat medium supplemented with different carbon sources according to an embodiment of the present invention. Fig. 10 is a comparison of the harvesting results of adding different carbon sources to the oat medium according to the embodiment of the present invention. Fig. 11 shows the growth conditions of the oat medium supplemented with different nitrogen sources according to an embodiment of the present invention. FIG. 12 is a comparison of the harvesting results of adding different nitrogen sources to the oat medium according to the embodiment of the present invention. Fig. 13 shows the growth conditions of the oat medium with different additives according to the embodiment of the present invention. Fig. 14 shows the growth conditions of the oat medium with different additives according to the embodiment of the present invention. Fig. 15 is a comparison of the harvest results of the oat medium with different additives according to the embodiment of the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109120844A TWI739482B (en) | 2020-06-19 | 2020-06-19 | Medium and method for improving cordycepin and pentostatin production of cordyceps militaris |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109120844A TWI739482B (en) | 2020-06-19 | 2020-06-19 | Medium and method for improving cordycepin and pentostatin production of cordyceps militaris |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI739482B TWI739482B (en) | 2021-09-11 |
TW202200779A true TW202200779A (en) | 2022-01-01 |
Family
ID=78778120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109120844A TWI739482B (en) | 2020-06-19 | 2020-06-19 | Medium and method for improving cordycepin and pentostatin production of cordyceps militaris |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI739482B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118028121B (en) * | 2024-04-09 | 2024-07-02 | 北京市科学技术研究院 | Cordyceps militaris strain for high-yield cordycepin and pravastatin as well as culture method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI472614B (en) * | 2013-08-14 | 2015-02-11 | Univ Chung Chou Sci & Tech | Method for cultivation of cordyceps militaris using supercritical fluid extraction of brown rice |
CN110367038B (en) * | 2019-03-22 | 2021-09-14 | 山西万海澳生物科技有限责任公司 | Production method of high-efficiency anti-cancer cordyceps militaris |
-
2020
- 2020-06-19 TW TW109120844A patent/TWI739482B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TWI739482B (en) | 2021-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107502555A (en) | The fermentation medium and its zymotechnique of a kind of mortierella Diding | |
CN102643884A (en) | Method for producing polysaccharide by utilizing fermentation of ganoderma | |
CN101531968B (en) | Method for improving output of cordyceps militars fruiting body and cordycepin by adopting red yeast rice synergistic fermentation | |
CN105400842A (en) | Method for increasing yield of paclitaxel in endophytic fungus fermentation product | |
KR20100021110A (en) | Medium composition for phellinus linteus culture | |
TW202200779A (en) | Medium and method for improving cordycepin and pentostatin production of cordyceps militaris | |
CN100420679C (en) | Novel compound, bacteria strain and method for producing novel compound using the strain | |
CN107298670A (en) | Come from penicillium oxalicum secalonic acid H and prepare anti-human oral cavity epidermoid carcinoma medicinal application | |
CN100567318C (en) | Nucleoside active matter in the artificial culture Cordyceps militaris (L.) Link. and its production and use | |
CN107298669A (en) | Come from the secalonic acid I of penicillium oxalicum and anti-human oral cavity epidermoid carcinoma medicinal application | |
CN103724290A (en) | Cyclopeptide compound clavatustide A as well as producing strain, preparation method and application thereof | |
CN105061446B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting nasopharyngeal carcinoma | |
TWI385248B (en) | A formula of culturing medium for cordyceps spp. | |
KR100693493B1 (en) | Mass culturing method of mycelium of Ganoderma applanatum | |
Li et al. | Isolation of new strain of Cordyceps militaris HB8 and optimal condition for production of adenosine and cordycepin in fruit body | |
CN112175843B (en) | Aureobasidium pullulans with improved beta-glucan yield and application thereof | |
Jian et al. | Effect of plant growth regulator on cordycepin and adenosine production of Cordyceps militaris cultured on wheat solid substrate. | |
CN104250621A (en) | Sea streptomyces cinereoruber and method of applying same to prepare aurone compound | |
CN110229131B (en) | Benzopyrone derivative derived from cerasus humilis endophytic fungi as well as preparation method and application thereof | |
CN1212387C (en) | Fine rod bundle spore SX-1 separated and cultured from cordyceps and its saparation, culture process and use | |
CN103641791B (en) | Cyclopeptide compound clavatustide B, and preparation method and application thereof | |
US20090203775A1 (en) | Novel compound and a novel microorganism for producing the novel compound | |
CN112314325A (en) | Method for culturing artificial cordyceps militaris sporocarp | |
Wiengmoon et al. | Mycelial growth and fruiting body production of Cordyceps militaris in different culture chambers | |
Curvetto et al. | Sunflower seed-based medium for growth of Ganoderma spp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |